Abstract:Objective: To investigate whether LY01008, a locally developed bevacizumab biosimilar agent, is appropriate for widespread use among Chinese advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC) patients, our current study was designed to evaluate the cost-effectiveness of first-line LY01008 combined with platinum-doublet chemotherapy versus chemotherapy alone from the perspective of the Chinese healthcare system.Material and Methods: This economic evaluation designed a Markov model to compare the healthcare cost and quality-adjusted life-year (QALY) of first-line LY01008 combined with chemotherapy versus first-line chemotherapy. Transition probabilities, including disease progression, survival, and adverse event (AE)-related discontinuation of first-line treatment, were estimated using data from the clinical trials. Costs and health utilities were derived from local databases, hospitals, and published literature. Our base case analysis and scenario analysis focused on the cost-effectiveness of chemotherapy combined with a clinical trial dosage (15 mg/kg every 3-week cycle) and a real-world dosage (7.5 mg/kg every 3-week cycle) of LY01008, respectively.Results: In the base case analysis, first-line LY01008 combined with chemotherapy was associated with an increase of 0.48 QALYs in effectiveness and an increase of CNY 189,988 (US$ 26,240) in healthcare costs compared with first-line chemotherapy, resulting an incremental cost-effectiveness ratio (ICER) of CNY 375,425 (US$ 54,430)/QALY. In the scenario analysis, first-line LY01008 combined with chemotherapy was associated with a mean healthcare cost of CNY 265,060 (US$ 38,429), resulting an ICER of CNY 221,579 (US$ 32,125/QALY) between first-line LY01008 combined with chemotherapy versus first-line chemotherapy. The parameters that determine the cost of LY01008 have the greatest impact on the cost-effectiveness results.Conclusion: From the perspective of the Chinese healthcare system, first-line LY01008 at a real-world dosage combined with chemotherapy is likely to represent a cost-effective strategy compared with first-line chemotherapy alone for Chinese advanced or recurrent nonsquamous NSCLC patients.

Cost-effectiveness analysis of anlotinib plus chemotherapy with or without benmelstobart versus chemotherapy alone for extensive-stage small-cell lung cancer in China

Comparative Cost-Effectiveness of Tislelizumab Plus Chemotherapy Versus Standard Chemotherapy in First-Line Treatment for Extensive-Stage Small Cell Lung Cancer: Perspectives from the U.S. and Chinese Healthcare Systems

Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China

A Trial-Based Cost-Effectiveness Analysis Of Erlotinib Alone Versus Platinum-Based Doublet Chemotherapy As First-Line Therapy For Eastern Asian Nonsquamous Non-Small-Cell Lung Cancer

Cost-effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Extensive Small Cell Lung Cancer in China.

OPTIMAL and ENSURE Trials-Based Combined Cost-Effectiveness Analysis of Erlotinib Versus Chemotherapy for the First-Line Treatment of Asian Patients with Non-Squamous Non-Small-cell Lung Cancer.

Cost-effectiveness analysis of serplulimab combination therapy versus chemotherapy alone for patients with extensive-stage small cell lung cancer

Updated Cost-Effectiveness Analysis of Adebrelimab Plus Chemotherapy for Extensive-Stage Small Cell Lung Cancer in China

Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer

Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial

First-line Atezolizumab Plus Chemotherapy in Treatment of Extensive Small Cell Lung Cancer: a Cost-Effectiveness Analysis from China

Cost-Effectiveness Analysis of 6 Tyrosine Kinase Inhibitors as First-Line Treatment for ALK-Positive NSCLC in China

First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China.

First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis

Model-Based Economic Evaluation of Ceritinib and Platinum-Based Chemotherapy As First-Line Treatments for Advanced Non-Small Cell Lung Cancer in China

Cost-effectiveness of Afatinib, Gefitinib, Erlotinib and Pemetrexed-Based Chemotherapy As First-Line Treatments for Advanced Non-Small Cell Lung Cancer in China.

Cost-effectiveness of Anlotinib Vs. Pembrolizumab and Nivolumab As Third-Line Treatment in Recurrent Small Cell Lung Cancer in China

Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China

Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China

Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined with Chemotherapy As First-Line Treatment for Chinese Patients with Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer